Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Precise Biometrics AB is a Sweden-based software and SaaS company specializing in biometrics and cybersecurity solutions. Headquartered in Lund with additional offices in Stockholm, Potsdam NY, Seoul, Taipei, and Shanghai, it operates through two main business units: Digital Identity and Biometric Technologies. The company develops AI-powered biometric recognition software for fingerprint, face, and palm authentication, featuring advanced matching and anti-spoofing algorithms used over 100,000 times per second globally. These solutions enable secure and seamless access in key sectors including mobile phones, laptops, automotive for driver authentication and in-car payments, smart locks, logical and physical access, visitor management, and government ID programs. Precise Biometrics AB also provides turnkey systems like Precise Visit by EastCoast, a cloud-based visitor management platform trusted by over 800 customers, and Precise Access for facial or palm-based physical entry. Founded in 1997, the company holds a pioneering role in the biometric industry, balancing high security with user-friendly experiences across three continents.
kr 0.17
kr 0.01 (-5.10%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-25.78% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 10.4% YoY. Margins deteriorated 14.9pp alongside, both lines moving the wrong way.
ROIC dropped from -4.58% to -10.47%, capital efficiency is deteriorating. Negative free cash flow of -kr 11M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 75M
▼ -10.4% YoY
Net Income (TTM)
-kr 18M
▼ -136.3% YoY
Op. Margin
-25.17%
▼ -14.9pp YoY
ROIC
-10.47%
▼ -5.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 9M
▼ -757.4% YoY
Op. Cash Flow (TTM)
-kr 4M
▼ -967.0% YoY
Net Debt
-kr 8M
Net Cash Position
Cash & Equiv.
kr 18M
3Y CAGR: -5.1%
Continue Research
Precise Biometrics AB (PREC.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Precise Biometrics AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Precise Biometrics AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -25.2% operating margin and a -10.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PREC.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.